NASDAQ : RTSN
Retension Pharmaceuticals, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 11.83 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 98.56M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Selling, General & Admin | 2.43M | 1.77M | 976.37K | 248.86K |
| Research & Development | 12.44M | 5.11M | 1.30M | 20.00K |
| Operating Expenses | 14.86M | 6.88M | 2.28M | 268.86K |
| Operating Income | -14.86M | -6.88M | -2.28M | -268.86K |
| Interest & Investment Income | 618.00K | 579.36K | 356.51K | 61.47K |
| Other Non Operating Income (Expenses) | 15.07K | |||
| Pretax Income | -14.24M | -6.30M | -1.91M | -207.39K |
| Net Income | -14.24M | -6.30M | -1.91M | -207.39K |
| Net Income to Common | -14.24M | -6.30M | -1.91M | -207.39K |
| Shares Outstanding (Basic) | 806.07K | 805.15K | 805.15K | 805.15K |
| Shares Outstanding (Diluted) | 806.07K | 805.15K | 805.15K | 805.15K |
| EPS (Basic) | -17.67 | -7.83 | -2.37 | -0.26 |
| EPS (Diluted) | -17.67 | -7.83 | -2.37 | -0.26 |
| EBIT | -14.86M | -6.88M | -2.28M | -268.86K |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Cash & Equivalents | 13.49M | 18.90M | 8.19M | 6.33M |
| Cash & Short-Term Investments | 13.49M | 18.90M | 8.19M | 6.33M |
| Prepaid Expenses | 2.63M | 2.54M | 184.66K | |
| Total Current Assets | 16.13M | 21.45M | 8.37M | 6.33M |
| Total Assets | 16.13M | 21.45M | 8.37M | 6.33M |
| Accounts Payable | 2.79M | 775.86K | 194.44K | 23.89K |
| Accrued Expenses | 83.31K | 136.31K | 75.65K | 32.60K |
| Other Current Liabilities | 6.87K | 114.96K | ||
| Total Current Liabilities | 2.88M | 912.17K | 276.97K | 171.45K |
| Total Liabilities | 2.88M | 912.17K | 276.97K | 171.45K |
| Common Stock | 501.00 | 81.00 | 81.00 | 500.00 |
| Additional Paid-In Capital | 917.69K | 532.18K | 287.15K | |
| Retained Earnings | -15.84M | -8.32M | -2.01M | -104.20K |
| Total Common Equity | -14.92M | -7.78M | -1.73M | -103.70K |
| Shareholders' Equity | 13.25M | 20.53M | 8.09M | 6.15M |
| Total Liabilities & Equity | 16.13M | 21.45M | 8.37M | 6.33M |
| Net Cash (Debt) | 13.49M | 18.90M | 8.19M | 6.33M |
| Net Cash Per Share | 16.74 | 23.48 | 10.17 | 7.86 |
| Filing Date Shares Outstanding | 807.48K | 807.48K | 805.15K | 805.15K |
| Total Common Shares Outstanding | 807.48K | 807.48K | 805.15K | 805.15K |
| Working Capital | 13.25M | 20.53M | 8.09M | 6.15M |
| Book Value Per Share | -18.48 | -9.64 | -2.14 | -0.13 |
| Tangible Book Value | -14.92M | -7.78M | -1.73M | -103.70K |
| Tangible Book Value Per Share | -18.48 | -9.64 | -2.14 | -0.13 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Net Income | -14.24M | -6.30M | -1.91M | -207.39K |
| Stock-Based Compensation | 420.48K | 245.04K | 140.73K | |
| Other Operating Activities | -151.01K | -15.07K | ||
| Change in Accounts Payable | 2.33M | 581.41K | 170.56K | 47.78K |
| Change in Other Net Operating Assets | -244.53K | -2.31M | -141.61K | 78.94K |
| Operating Cash Flow | -11.89M | -7.78M | -1.76M | -80.68K |
| Financing Cash Flow | 7.12M | 18.50M | 3.61M | 12.73M |
| Net Cash Flow | -4.77M | 10.72M | 1.86M | 12.65M |
| Levered Free Cash Flow | -5.78M | -1.36M | ||
| Unlevered Free Cash Flow | -5.78M | -1.36M | ||
| Change in Working Capital | 2.08M | -1.72M | 28.95K | 126.72K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Market Capitalization | 94.15M | |||
| Enterprise Value | 80.65M | |||
| Net Debt / Equity Ratio | -1.02 | -0.92 | -1.01 | -1.03 |
| Quick Ratio | 4.69 | 20.72 | 29.55 | 36.89 |
| Current Ratio | 5.61 | 23.51 | 30.22 | 36.89 |
| Return on Equity (ROE) | -44.02% | -26.81% | ||
| Return on Assets (ROA) | -28.85% | -19.41% | ||
| Return on Capital Employed (ROCE) | -112.10% | -33.50% | -28.20% | -4.40% |
| Buyback Yield / Dilution | -0.11% | 0.00% |